MCM
TEVA icon

Mainstay Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Mainstay Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-800
Closed -$17K – 347
2018
Q3 		$17K Hold
800
– – 0.01% 302
2018
Q2 		$19K Buy
+800
New +$16.3K 0.02% 276

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Mainstay Capital Management's TEVA Position: Q4 2018 in Review

Mainstay Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 800 shares — an estimated $17K sold.

Mainstay Capital Management first reported a position in TEVA in Q2 2018 and held it in 2 quarters. The position peaked at $19K in Q2 2018. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Mainstay Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 800 Teva Pharmaceuticals shares in Q4 2018, an estimated $17K.
  • Mainstay Capital Management first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Mainstay Capital Management's Teva Pharmaceuticals position peaked at $19K in Q2 2018.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.